内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NKTR 内克塔治疗

盘后交易 01-12 17:57:12 EST

38.77

-0.94

-2.37%

盘后39.00

+0.23+0.59%

17:22 EST

最高39.71	最低37.35	成交量119.50万
今开39.71	昨收39.71	日振幅5.96%
总市值7.89亿	流通市值6.82亿	总股本2,034万
成交额4,552万	换手率6.79%	流通股本1,759万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":38.77,"timestamp":1768251600000,"preClose":39.71,"halted":0,"volume":1194963,"hourTrading":{"tag":"盘后","latestPrice":39,"preClose":38.77,"latestTime":"17:22 EST","volume":5747,"amount":222841.20658099998,"timestamp":1768256526879},"delay":0,"floatShares":17594200,"shares":20341589,"eps":-7.899717,"marketStatus":"盘后交易","change":-0.94,"latestTime":"01-12 17:57:12 EST","open":39.71,"high":39.71,"low":37.345,"amount":45523324.787556,"amplitude":0.059557,"askPrice":39,"askSize":20,"bidPrice":38.18,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-7.899717,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768266000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":39.71,"preHourTrading":{"tag":"盘前","latestPrice":39.26,"preClose":39.71,"latestTime":"09:23 EST","volume":2004,"amount":79753.456536,"timestamp":1768227830709},"postHourTrading":{"tag":"盘后","latestPrice":39,"preClose":38.77,"latestTime":"17:22 EST","volume":5747,"amount":222841.20658099998,"timestamp":1768256526879},"volumeRatio":2.136581,"impliedVol":0.9834,"impliedVolPercentile":0.452},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2602349969","title":"内克塔治疗盘中异动 临近收盘急速下跌5.19%报41.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602349969","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602349969?lang=zh_cn&edition=full","pubTime":"2026-01-09 04:37","pubTimestamp":1767904648,"startTime":"0","endTime":"0","summary":"北京时间2026年01月09日04时37分，内克塔治疗股票出现异动，股价大幅下跌5.19%。截至发稿，该股报41.25美元/股，成交量37.2958万股，换手率1.83%，振幅5.61%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为1.90%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109043728a4ad3e5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109043728a4ad3e5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2595117357","title":"内克塔治疗盘中异动 大幅下跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595117357","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595117357?lang=zh_cn&edition=full","pubTime":"2025-12-30 03:46","pubTimestamp":1767037570,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日03时46分，内克塔治疗股票出现异动，股价急速下挫5.03%。截至发稿，该股报42.25美元/股，成交量46.1589万股，换手率2.27%，振幅4.65%。机构评级方面，在所有9家参与评级的机构中，89%的券商给予买入建议，11%的券商给予持有建议，无券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.64%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230034610a48722ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230034610a48722ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1111891041","title":"Nektar Therapeutics股价在盘前交易中下跌2.4%，因其自身免疫疾病药物未能达到中期研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1111891041","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111891041?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:45","pubTimestamp":1765892748,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics股价在盘前交易中下跌2.4%，因其自身免疫疾病药物未能达到中期研究的主要目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1180977691","title":"内克塔治疗 - Rezolve-Aa二期B研究结果支持进入斑秃的三期开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1180977691","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180977691?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:16","pubTimestamp":1765890968,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezolve-Aa二期B研究结果支持进入斑秃的三期开发","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1190845593","title":"内克塔治疗 - Rezpegaldesleukin治疗组均满足统计显著性标准，排除违规情况","url":"https://stock-news.laohu8.com/highlight/detail?id=1190845593","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190845593?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:07","pubTimestamp":1765890469,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezpegaldesleukin治疗组均满足统计显著性标准，排除违规情况","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1101661185","title":"内克塔治疗 - Rezolve-Aa II期B研究达成目标产品特征，盐分评分降低28.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101661185","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101661185?lang=zh_cn&edition=full","pubTime":"2025-12-16 21:07","pubTimestamp":1765890441,"startTime":"0","endTime":"0","summary":"内克塔治疗 - Rezolve-Aa II期B研究达成了目标产品特征，盐分评分降低了28.2%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"1125532009","title":"Nektar将在2025年12月16日召开电话会议，讨论其Rezolve-Aa II期研究中Rezpegaldesleukin在脱发症中的36周诱导治疗期的初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1125532009","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125532009?lang=zh_cn&edition=full","pubTime":"2025-12-16 07:00","pubTimestamp":1765839610,"startTime":"0","endTime":"0","summary":"Nektar将在2025年12月16日召开电话会议，讨论其Rezolve-Aa II期研究中Rezpegaldesleukin在脱发症中的36周诱导治疗期的初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1173506245","title":"Nektar Therapeutics第三季度每股收益为-1.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173506245","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173506245?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:04","pubTimestamp":1763571844,"startTime":"0","endTime":"0","summary":"11月6日 - 内克塔治疗第三季度的运营收入为-316,720,000美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2583275656","title":"内克塔治疗2025财年第三财季实现净利润-35.52百万美元，同比增加4.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583275656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583275656?lang=zh_cn&edition=full","pubTime":"2025-11-16 00:02","pubTimestamp":1763222561,"startTime":"0","endTime":"0","summary":"11月16日，内克塔治疗公布财报，公告显示公司2025财年第三财季净利润为-35.52百万美元，同比增加4.16%；其中营业收入为11.79百万美元，同比减少51.12%，每股基本收益为-1.87美元。从资产负债表来看，内克塔治疗总负债2.16亿美元，其中短期债务22.18百万美元，资产负债比为1.40，流动比率为0.05。机构评级：截至2025年11月16日，当前有7家机构对内克塔治疗目标价做出预测，其中目标均价为93.86美元，其中最低目标价为30.00美元，最高目标价为120.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111600033095068119&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111600033095068119&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR"],"gpt_icon":0},{"id":"2583226656","title":"内克塔治疗盘中异动 急速拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583226656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583226656?lang=zh_cn&edition=full","pubTime":"2025-11-15 03:10","pubTimestamp":1763147426,"startTime":"0","endTime":"0","summary":"北京时间2025年11月15日03时10分，内克塔治疗股票出现波动，股价大幅上涨5.21%。截至发稿，该股报56.76美元/股，成交量35.4551万股，换手率1.74%，振幅7.41%。机构评级方面，在所有9家参与评级的机构中，78%的券商给予买入建议，11%的券商给予持有建议，11%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.90%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115031027a4a239c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251115031027a4a239c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"1194489688","title":"内克塔治疗宣布Rezpegaldesleukin的Rezolve-Ad 2B期试验结果入选2025年欧洲皮肤病与性病学会年会重磅口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1194489688","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194489688?lang=zh_cn&edition=full","pubTime":"2025-09-09 19:01","pubTimestamp":1757415708,"startTime":"0","endTime":"0","summary":"内克塔治疗宣布Rezpegaldesleukin的Rezolve-Ad 2B期试验结果入选2025年欧洲皮肤病与性病学会年会重磅口头报告","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2561483893","title":"内克塔治疗盘中异动 股价大跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561483893","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561483893?lang=zh_cn&edition=full","pubTime":"2025-08-20 22:17","pubTimestamp":1755699448,"startTime":"0","endTime":"0","summary":"北京时间2025年08月20日22时17分，内克塔治疗股票出现波动，股价急速下挫5.12%。截至发稿，该股报25.35美元/股，成交量9.5023万股，换手率0.50%，振幅5.46%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.57%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820221728a6f16568&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250820221728a6f16568&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2557957859","title":"内克塔治疗盘中异动 早盘大幅拉升7.40%报23.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557957859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557957859?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:32","pubTimestamp":1754659946,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时32分，内克塔治疗股票出现波动，股价急速拉升7.40%。截至发稿，该股报23.36美元/股，成交量2.0432万股，换手率0.12%，振幅2.07%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.08%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213226a6db2070&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213226a6db2070&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2556817899","title":"内克塔治疗盘中异动 早盘股价大涨5.13%报22.79美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556817899","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556817899?lang=zh_cn&edition=full","pubTime":"2025-08-01 23:12","pubTimestamp":1754061141,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日23时12分，内克塔治疗股票出现异动，股价急速拉升5.13%。截至发稿，该股报22.79美元/股，成交量19.0473万股，换手率1.10%，振幅7.82%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.03%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080123122194c933ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080123122194c933ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2555708781","title":"内克塔治疗盘中异动 股价大跌5.16%报23.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555708781","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555708781?lang=zh_cn&edition=full","pubTime":"2025-07-28 23:44","pubTimestamp":1753717458,"startTime":"0","endTime":"0","summary":"北京时间2025年07月28日23时44分，内克塔治疗股票出现波动，股价大幅下挫5.16%。截至发稿，该股报23.71美元/股，成交量23.6647万股，换手率1.37%，振幅6.80%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.02%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072823441994bf9fbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072823441994bf9fbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2553818296","title":"内克塔治疗7月22日成交额为1434.03万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553818296","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553818296?lang=zh_cn&edition=full","pubTime":"2025-07-23 12:22","pubTimestamp":1753244572,"startTime":"0","endTime":"0","summary":"美东时间2025年7月22日，内克塔治疗成交额为1434.03万美元，成交额较昨日减少3.45%，当日成交量为58.01万股。内克塔治疗于2025年7月22日跌1.25%，报24.48美元，该股过去5个交易日涨2.86%，年初至今涨75.48%，过去60日涨121.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723122254a45decb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723122254a45decb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2553251289","title":"内克塔治疗7月21日成交额为1485.21万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553251289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553251289?lang=zh_cn&edition=full","pubTime":"2025-07-22 12:19","pubTimestamp":1753157963,"startTime":"0","endTime":"0","summary":"美东时间2025年7月21日，内克塔治疗成交额为1485.21万美元，成交额较昨日减少48.00%，当日成交量为59.80万股。内克塔治疗于2025年7月21日跌0.6%，报24.79美元，该股过去5个交易日涨1.56%，年初至今涨77.71%，过去60日涨140.91%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722121927a45b3b62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722121927a45b3b62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2552945903","title":"内克塔治疗7月17日成交额为3353.97万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552945903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552945903?lang=zh_cn&edition=full","pubTime":"2025-07-18 12:16","pubTimestamp":1752812171,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日，内克塔治疗成交额为3353.97万美元，成交额较昨日增加45.96%，当日成交量为131.13万股。内克塔治疗于2025年7月17日涨10.48%，报26.67美元，该股过去5个交易日涨6.25%，年初至今涨91.18%，过去60日涨184.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718121612a6b1307b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718121612a6b1307b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2552170681","title":"内克塔治疗7月16日成交额为2297.95万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552170681","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552170681?lang=zh_cn&edition=full","pubTime":"2025-07-17 12:15","pubTimestamp":1752725742,"startTime":"0","endTime":"0","summary":"美东时间2025年7月16日，内克塔治疗成交额为2297.95万美元，成交额较昨日减少16.15%，当日成交量为95.85万股。内克塔治疗于2025年7月16日涨1.43%，报24.14美元，该股过去5个交易日涨3.34%，年初至今涨73.05%，过去60日涨153.04%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717121544a6aed4b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717121544a6aed4b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2551619579","title":"内克塔治疗盘中异动 早盘股价大跌5.13%报23.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551619579","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551619579?lang=zh_cn&edition=full","pubTime":"2025-07-15 23:25","pubTimestamp":1752593125,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日23时25分，内克塔治疗股票出现异动，股价快速跳水5.13%。截至发稿，该股报23.16美元/股，成交量33.2685万股，换手率1.92%，振幅6.45%。机构评级方面，在所有8家参与评级的机构中，75%的券商给予买入建议，13%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.25%。内克塔治疗公司简介：Nektar Therapeutics 是一家临床阶段，以研究为基础的药物发现生物制药公司，专注于发现和开发免疫治疗领域的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507152325259543a405&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507152325259543a405&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0854},{"period":"1month","weight":-0.3123},{"period":"3month","weight":-0.2692},{"period":"6month","weight":0.5878},{"period":"1year","weight":1.3222},{"period":"ytd","weight":-0.0608}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立，并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司，专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内，该公司致力于创造新的免疫调节剂，选择性地诱导、放大、减弱或阻止免疫反应，以达到预期的治疗效果。","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.039629},{"month":2,"riseRate":0.516129,"avgChangeRate":0.003089},{"month":3,"riseRate":0.387097,"avgChangeRate":-0.002052},{"month":4,"riseRate":0.451613,"avgChangeRate":0.01158},{"month":5,"riseRate":0.354839,"avgChangeRate":0.003107},{"month":6,"riseRate":0.40625,"avgChangeRate":0.024924},{"month":7,"riseRate":0.4375,"avgChangeRate":-0.019557},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}